Iron deficiency is very common in patients with heart failure and is associated with exercise intolerance, reduced quality of life, increased mortality, and higher risk of hospitalization, regardless of the presence of anemia. Clinical studies have previously demonstrated the positive effect of intravenous administration of ferric carboxymaltose (FCM) in patients with chronic heart failure with reduced ejection fraction of the left ventricle. The AFFIRM-AHF study investigated the effect of FCM administration initiated shortly before…